ISODIOL INTERNATIONAL INC. ANNOUNCES LAUNCHING PHYTOCEUTICAL DIVISION

September 5th, 2017 -- Vancouver, BC -- InvestorsHub Newswire -- Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabinoid innovator specializing in the development of pharmaceutical and consumer products announces that it is proud to be launching a new Phytoceutical Division that will focus on cannabinoids and terpenes derived from non-cannabis sources.

Proprietary extraction methods ensure that the cannabinoids and terpenes will not be denatured during extraction and this process will provide another superior product in the Isodiol offerings. The discovery of cannabinoids in non-cannabis plants and the proprietary methodology developed to extract them is a revolutionary development in the industry and will provide an opportunity to manufacture and distribute medicinal and consumer products into markets that presently have restrictions on such products.

Marcos Agramont, CEO, says "We are excited to be launching this new division and some of the first new products we will be bringing to the market will be CBD based which will not be derived from the cannabis plant. These highly innovative new products will open up our ability to sell into International markets much faster due to less regulations and restrictions surrounding our non-cannabis derived source of the CBD. In addition, we are confident in this new product line’s superb efficacy, which, in some cases, has demonstrated greater effectiveness than many cannabis derived products currently on the market."

The Company will provide additional information on the commercialization strategy of this division in the coming weeks.

About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of a 99%+ pure pharmaceutical grade cannabinoid crystalline isolate derived from exempt parts of the hemp plant, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

ON BEHALF OF THE BOARD : “Marcos Agramont”  CEO & Director
CORPORATE MEDIA: [e-mail]   www.isodiol.com
Join Us On Face Book: https://www.facebook.com/isodiol/
Twitter: @isodiol

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
 
The CSE has not reviewed, approved or disapproved the content of this press release.